H Ito1, H Ito1, S Nakano, H Kusaka. 1. Department of Neurology, Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan. hishashi.ito@tokushukai.jp
Abstract
OBJECTIVE: To investigate the efficacy of low dose of botulinum toxin type A (BTX-A) for facial synkinesis and hyperlacrimation. MATERIAL AND METHODS: Eleven patients suffering from facial synkinesis after Bell's palsy or facial nerve injury were treated with a low dose of BTX-A, 0.5-1.25 U per point into several points. One patient showing hyperlacrimation was also treated with BTX-A. The whole observational period was 43 months. RESULTS: On average, 5.76 U of BTX-A, which was lower than that of previous reports, was injected per treatment. In seven cases, synkinesis disappeared completely after three or fewer sessions of BTX-A injection. The mean interval between treatments was 14.5 weeks. Hyperlacrimation was completely suppressed after a single subcutaneous injection of BTX-A. Only mild subcutaneous hemorrhage was observed as adverse reactions. CONCLUSION: Facial synkinesis can be treated with a lower dose of BTX-A without relevant adverse reactions.
OBJECTIVE: To investigate the efficacy of low dose of botulinum toxin type A (BTX-A) for facial synkinesis and hyperlacrimation. MATERIAL AND METHODS: Eleven patients suffering from facial synkinesis after Bell's palsy or facial nerve injury were treated with a low dose of BTX-A, 0.5-1.25 U per point into several points. One patient showing hyperlacrimation was also treated with BTX-A. The whole observational period was 43 months. RESULTS: On average, 5.76 U of BTX-A, which was lower than that of previous reports, was injected per treatment. In seven cases, synkinesis disappeared completely after three or fewer sessions of BTX-A injection. The mean interval between treatments was 14.5 weeks. Hyperlacrimation was completely suppressed after a single subcutaneous injection of BTX-A. Only mild subcutaneous hemorrhage was observed as adverse reactions. CONCLUSION:Facial synkinesis can be treated with a lower dose of BTX-A without relevant adverse reactions.
Authors: Anna M Demetriades; Ilya M Leyngold; Sam D'Anna; Allen O Eghrari; Dave G Emmert; Michael P Grant; Shannath L Merbs Journal: Ophthalmic Plast Reconstr Surg Date: 2013 Jan-Feb Impact factor: 1.746
Authors: Justin R Shinn; Nkechi N Nwabueze; Liping Du; Priyesh N Patel; Kevin K Motamedi; Cathey Norton; William R Ries; Scott J Stephan Journal: JAMA Facial Plast Surg Date: 2019-05-01 Impact factor: 4.611